Charles River Laboratories International (CRL)'s stock has been on a roller coaster ride according to recent reports. Its valuation and stock performance have been under constant scrutiny, owing to the volatility of its share price which rebounded recently. Positive news included analyst upgrades by William Blair and Barclays, successful toxicity testing through a partnership with Toxys and strong sales report in Q1 of 2025. However, some negative reports drew attention to an underperformance when compared to competitors and downgraded ratings by Weiss and Wall Street Zen. Despite a dip in its reception, several firms including Lecap Asset Management and Fifth Third Bancorp have invested notably in CRL. Renewed optimism and ongoing growth extend from their expansion of oncology partnerships, reaffirmation of guidance and CFO transition. The company also announced governance updates and plans for a strategic review.
Charles River Laboratories International CRL News Analytics from Wed, 19 Feb 2025 08:00:00 GMT to Sat, 11 Oct 2025 14:05:47 GMT -
Rating 5
- Innovation 6
- Information 7
- Rumor -5
